21/11/22 -"The increase in our EPS estimate is attributable to the upgraded FY22 guidance, which includes: 1) same-day sales growth of c.12% (vs 7-9% previously), and 2) an adjusted EBITA margin of c. 7.2% (vs ..."
You may also be interested by these reports :
The outlook for the German online pharmacy market in 2023E is positive. Zur Rose G. lost market share in 2022
The divestment of group’s Swiss business will delay the way to adj. EBITDA profitability; Add confirmed but lower TP
We now take a more conservative view on Currys’ performance in the Nordics segment (c.40% of group revenue and c.47% operating profit in FY21/22). ...
FY23E: Sales to decline yoy, adj. EBITDA break-even postponed to FY24E